ASLAN Keeps Eye On Maximizing Values After Fundraising
This article was originally published in PharmAsia News
Executive Summary
ASLAN has closed a Series C round involving some new investors that puts the Singapore venture in a more comfortable financial position and may allow it to complete pivotal trials for its lead oncology project. But its CEO says the main focus will continue to be on maximizing asset values.
You may also be interested in...
VC Roundup: 2Q Financings Fall As Per-Company Averages Rise
Second quarter venture capital investment in biotech fell from the same period a year ago, but the total remains near record levels, since some early-stage companies have been able to raise big VC sums.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Teva’s immunology biosimilar launches; Intra-Cellular’s promising depression data; Phase III sleep apnea win for Lilly’s tirzepatide; an interview with Viking’s CEO; and China looks to define innovative drugs.